Influence of the prodrugs 5‐fluorocytosine and CPT‐11 on ovarian cancer cells using genetically engineered stem cells: tumor‐tropic potential and inhibition of ovarian cancer cell growth
Open Access
- 2 February 2010
- journal article
- Published by Wiley in Cancer Science
- Vol. 101 (4) , 955-962
Abstract
Recent studies have shown that genetically engineered stem cells (GESTECs) to produce suicide enzymes that convert non‐toxic prodrugs to toxic metabolites selectively migrate toward tumor sites and reduce tumor growth. In the present study, we evaluated whether these GESTECs were capable of migrating to human ovarian cancer cells and examined the potential therapeutic efficacy of the gene‐directed enzyme prodrug therapy against ovarian cancer cellsin vitro. The expression of cytosine deaminase (CD) or carboxyl esterase (CE) mRNA of GESTECs was confirmed by RT‐PCR. A modified transwell migration assay was performed to determine the migratory capacity of GESTECs to ovarian cancer cells. GESTECs (HB1.F3.CD or HB1.F3.CE cells) engineered to express a suicide gene (CD or CE) selectively migrated toward ovarian cancer cells. A [3H] thymidine incorporation assay was conducted to measure the proliferative index. Treatment of human epithelial ovarian cancer cell line (SKOV‐3, an ovarian adenocarcinoma derived from the ascites of an ovarian cancer patient) with the prodrugs 5‐fluorocytosine (5‐FC) or camptothecin‐11 (CPT‐11) in the presence of HB1.F3.CD or HB1.F3.CE cells resulted in the inhibition of ovarian cancer cell growth. Based on the data presented herein, we suggest that GESTECs expressing CD/CE may have a potent advantage to selectively treat ovarian cancers.(Cancer Sci2010; 101: 955–962)Keywords
This publication has 43 references indexed in Scilit:
- Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapyAnti-Cancer Drugs, 2009
- Development of a Tumor-Selective Approach to Treat Metastatic CancerPLOS ONE, 2006
- Irinotecan in the treatment of colorectal cancerCancer Treatment Reviews, 2006
- Human Neural Stem Cells Target Experimental Intracranial Medulloblastoma and Deliver a Therapeutic Gene Leading to Tumor RegressionClinical Cancer Research, 2006
- Human Neural Stem Cell Transplantation Promotes Functional Recovery in Rats With Experimental Intracerebral HemorrhageStroke, 2003
- Transplantation of prodrug-converting neural progenitor cells for brain tumor therapyCancer Gene Therapy, 2003
- Sensitivity to Anticancer Agents and Resistance Mechanisms in Clear Cell Carcinoma of the OvaryJapanese Journal of Cancer Research, 2002
- In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferaseGene Therapy, 2001
- Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector Containing the E. coli Cytosine Deaminase Gene to Metastatic Colon Carcinoma of the Liver in Association with the Oral Administration of the Pro-Drug 5-Fluorocytosine. The New York Hospital-Cornell Medical Center, New York, NYHuman Gene Therapy, 1997
- In Vivo Adenovirus-Mediated Gene Transfer of the Escherichia coli Cytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-FluorocytosineHuman Gene Therapy, 1995